105 related articles for article (PubMed ID: 24428199)
1. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma.
Hong J; Kim JH; Lee KH; Ahn HK; Park S; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
Leuk Lymphoma; 2014 Oct; 55(10):2312-8. PubMed ID: 24428199
[TBL] [Abstract][Full Text] [Related]
2. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.
Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080
[TBL] [Abstract][Full Text] [Related]
3. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
El-Galaly TC; Jakobsen LH; Hutchings M; de Nully Brown P; Nilsson-Ehle H; Székely E; Mylam KJ; Hjalmar V; Johnsen HE; Bøgsted M; Jerkeman M
J Clin Oncol; 2015 Dec; 33(34):3993-8. PubMed ID: 26438115
[TBL] [Abstract][Full Text] [Related]
4. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
5. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
6. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
[TBL] [Abstract][Full Text] [Related]
7. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
[TBL] [Abstract][Full Text] [Related]
8. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
9. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.
Abel GA; Vanderplas A; Rodriguez MA; Crosby AL; Czuczman MS; Niland JC; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; LaCasce AS
Leuk Lymphoma; 2012 Jun; 53(6):1113-6. PubMed ID: 22098406
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
11. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
12. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
13. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
14. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy.
El-Sharkawi D; Basu S; Ocampo C; Qian W; D'Sa S; Hoskin PJ; Ardeshna KM
Leuk Lymphoma; 2012 Oct; 53(10):1949-52. PubMed ID: 22462615
[TBL] [Abstract][Full Text] [Related]
15. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
17. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J
Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993
[TBL] [Abstract][Full Text] [Related]
18. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
[TBL] [Abstract][Full Text] [Related]
19. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
Guppy AE; Tebbutt NC; Norman A; Cunningham D
Leuk Lymphoma; 2003 Jan; 44(1):123-5. PubMed ID: 12691151
[TBL] [Abstract][Full Text] [Related]
20. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
